Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

Register for Details

For more details on financing and valuation for Lyell, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Lyell's ticker symbol?

LYEL

What is Lyell's stock price?

1.67 as of 11/29/23

Lyell Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
3/5/2020 Series C $493MM raised $XXX.XX $XXX.XX
7/15/2019 Series AA $205MM raised $XXX.XX $XXX.XX
3/15/2019 Series B $162.15MM raised $XXX.XX $XXX.XX
10/10/2018 Series A $179.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Lyell

Forge green plus iconForge green minus icon

What is Lyell funding to date?

Lyell has raised $1.04B to date.
Forge green plus iconForge green minus icon

When was Lyell founded?

Lyell was founded in 2018.
Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.